IMRX

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tum

- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months - - Overall survival was comparable among patients with moderate and deeper tumor volume reductions, suggesting presence of tumor reduction may be more important than depth of response - - Findings support atebimetinib’s mechanisms designed to extend survival including tumor volume reduction and body mass preservation - NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. Poster Presentation Details:Title: MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib

- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume - NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Monday, September 14, 2026, from 5:00-5:30 pm ET The fireside chats will b

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –  - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 – - 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer - - In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related - NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE)

H.C. Wainwright initiated coverage of Immuneering with a rating of Buy and set a new price target of $14.00

10-Q - Immuneering Corp (0001790340) (Filer)

8-K - Immuneering Corp (0001790340) (Filer)

- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 -  - Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date - - Peer-reviewed publication in Cancer Research details atebimetinib’s broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass - - Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE)

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, atebimetinib produced deeper, more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib - - Atebimetinib was associated with favorable tolerability in preclinical models, consistent with Deep Cyclic Inhibitor technology’s design to decouple antitumor activity from the toxicity of continuous MAPK suppression - - In a preclinical cancer cachexia model, atebimetinib-treated animals sustained body weight near b

4 - Immuneering Corp (0001790340) (Issuer)

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the "Start Date"). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock ("Common Stock") with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the "Closing Price").

3 - Immuneering Corp (0001790340) (Issuer)

Cantor Fitzgerald initiated coverage of Immuneering with a rating of Overweight and set a new price target of $17.00

BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be

4 - Immuneering Corp (0001790340) (Issuer)

4 - Immuneering Corp (0001790340) (Issuer)

8-K - Immuneering Corp (0001790340) (Filer)

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. At Immuneering, Mr. Gengos will oversee financial strategy, capital allocation, in

4 - Immuneering Corp (0001790340) (Issuer)

4 - Immuneering Corp (0001790340) (Issuer)

4 - Immuneering Corp (0001790340) (Issuer)

4 - Immuneering Corp (0001790340) (Issuer)

4 - Immuneering Corp (0001790340) (Issuer)